Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Large ribosomal subunit protein uL24 (RPL26)
- Target
- RPL26
- Molecular classification
- Ribosomal protein, Structural constituent of ribosome, L24P protein family (also known as universal ribosomal protein uL24 family)
01
Overview
Large ribosomal subunit protein uL24 (RPL26) is a highly conserved protein constituent of the 60S ribosomal subunit that participates in the structure and function of cytosolic ribosomes. It binds to rRNA, contributing to ribosome assembly and optimal protein synthesis, and is critical for pre-rRNA processing and ribosome biogenesis. RPL26 is subject to post-translational modification by UFMylation, which regulates ER-associated protein synthesis. Mutations in RPL26 cause Diamond-Blackfan anemia 11, underscoring its essential role in hematopoiesis. There are no approved drugs that specifically target this protein, but it is of research interest for studies on translation regulation and ribosomopathies[1][2][3][4].
- Other names
- 60S ribosomal protein L26Ribosomal protein L26uL24DBA11L26
02
Mechanism of action
Not applicable for clinical drugs; UFMylation (attachment of UFM1 modifier to specific lysines) regulates RPL26’s function at the ER, influencing ribosome interactions and secretory protein biogenesis[1].
03
Biological functions
Protein synthesisrRNA bindingRibosome assemblyRegulation of pre-rRNA maturation and ribosome biogenesisModulation of ER protein homeostasis via UFMylation
04
Disease associations
Diamond-Blackfan anemia (specifically Diamond-Blackfan anemia 11)Other rare congenital anemias
05
Safety considerations
Loss of function or mutations can result in impaired erythropoiesis (red blood cell production) and congenital anemia[3].Essential for ribosomal integrity; off-target effects of translation inhibitors could theoretically affect RPL26 but are nonspecific.
06
Biomarkers
RPL26 mutation status can be used as a biomarker for some subtypes of Diamond-Blackfan anemia[3]
Beyond the preview
Go deeper on Large ribosomal subunit protein uL24 (RPL26).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Large ribosomal subunit protein uL24 (RPL26).